Effective Of Frovatriptan For Menstrual Migraine:a Meta-analysis

ObjectiveTo evaluate the effectiveness of Frovatriptan in patients with menstrual migraine.MethodsWe searched PubMed?OVID?EMbase?Cochrane Library?CNKI?VIP?and Wanfang data base,retrieval time from the dates of their establishment until April2016,and relevant journals such as Chinese Journal of Evidence-Based Medicine,Chinese Journal of Pain Medicine,Chinese Journal of Neurology at the same time,and got information about frovatriptan randomized controlled study of treating menstrual migraine.According to the Cochrane library provided systematic review methods,we evaluated the quality of selected literature,and extracted data from these literature,then using RevMan5.3 software to conducte a Meta-analysis.ResultsFiltered eventually included 8 randomized controlled trials.a total of 3373 samples were inculded.1.Curative effect of frovatriptan in treating acute migraine menstrual There were 5 RCTs been included in the evaluation,each bias after evaluation were moderate.Meta-analysis showed:(1)Two groups of 2-hour headache response rate was not statistically significant(RR =1.00,95%CI =0.77-1.28,P=0.97);(2)Two groups of 4-hour headache response rate was not statistically significant(RR =1.10,95%CI=0.75-1.60,P=0.63);(3)Two groups of 4-hour headache response rate was notstatistically significant(RR =1.01,95%CI =0.92-1.11,P=0.89);(4)Two groups of 2-hour pain free rate was not statistically significant(RR =0.97,95%CI =0.67-1.42,P=0.88);(5)Two groups of 4-hour pain free rate was not statistically significant(RR=1.15,95%CI =0.84-1.58,P=0.39);(6)Two groups of 24-hour pain free rate was not statistically significant(RR =1.04,95%CI =0.894-1.15,P=0.45);(7)Two groups of 24 hours of headaches relapse rate were of statistical significance(RR =0.5,95%CI=0.37-0.67,P<0.0 0001),frovatripan group 24-hour headache recurrence rate was significantly smaller than the other control groups.2.Curative effect of frovatriptan of prophylactic treatment for menstrual migraine 3 RCT studies were included,each bias in the evaluation were studied as moderate level.Meta-analysis showed:(1)frovatripan 2.5mg once daily migraine incidence was less than the placebo groups,the two groups was statistically significant(RR =0.77,95%CI =0.71-0.84,P<0.00001);(2)frovatripan 2.5mg twice daily migraine incidence was less than placebo groups,The two groups was statistically significant(RR =0.61,95%CI =0.55-0.67,P<0.00001);(3)frovatripan 2.5mg twice daily groups migraine incidence was less than 2.5mg once daily groups(RR =0.79,95%CI=0.71-0.88,P<0.00001)?3.Safety of frovatriptan Reported adverse reactions were mild to moderate,mainly was nausea,dizziness,fatigue,dry mouth,drowsiness,back pain.Cardiovascular aspects of the discomfort was rare,including hypertension and abnormal electrocardiogram,blood pressure fluctuations,reuse frovatripan every day does not aggravate headache.ConclusionsUsing frovatriptan may relief headache quickly.Compared with control group,there was no significant difference(in 2-hour,4-hour,24-hour headache response rate and pain off rate).But frovatripan headache recurrence rate can be reduced by 24 hours.To prevent migraine attacks,frovatriptan 2.5mg Qd and Bid are valid,while frovatriptan2.5mg Bid for better efficacy.It caused fewer adverse reactions,rarely severe adversereactions,mainly was nausea,dizziness,fatigue,dry mouth,drowsiness,back pain,hypertension and abnormal electrocardiogram,blood pressure fluctuations etc.Due to fewer literatures were included in the study,and the quailty was not high,we need more and more large sample studies to confirm these findings.